Cresco Labs Inc. (OTCMKTS:CRLBF) Receives $2.50 Average Target Price from Analysts

Cresco Labs Inc. (OTCMKTS:CRLBF - Get Free Report) has earned a consensus recommendation of "Buy" from the six brokerages that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $2.50.

Several research analysts recently issued reports on CRLBF shares. Roth Capital raised Cresco Labs from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 9th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cresco Labs in a report on Monday, August 12th. Finally, Ventum Cap Mkts upgraded shares of Cresco Labs to a "strong-buy" rating in a report on Friday, August 9th.

Cresco Labs Stock Down 4.3 %

Shares of Cresco Labs stock traded down $0.07 during trading hours on Thursday, reaching $1.64. The company's stock had a trading volume of 368,930 shares, compared to its average volume of 732,009. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.30 and a current ratio of 2.00. The stock's fifty day simple moving average is $1.66 and its two-hundred day simple moving average is $1.77. The company has a market capitalization of $798.45 million, a P/E ratio of -3.48 and a beta of 1.86. Cresco Labs has a one year low of $1.06 and a one year high of $2.65.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.15). The company had revenue of $184.36 million for the quarter, compared to analyst estimates of $184.26 million. Cresco Labs had a negative net margin of 23.07% and a negative return on equity of 17.03%. On average, research analysts forecast that Cresco Labs will post -0.15 earnings per share for the current year.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.